NovaQuest Capital provides strategic capital to life science and healthcare companies. With experience managing over $3.0 billion of investor capital, the firm provides a robust life sciences and healthcare platform focused on promoting the development and growth of next generation drugs and technologies within the pharmaceutical and healthcare industries.
NovaQuest Capital is headquartered in Raleigh, North Carolina.
NovaQuest Capital Management has a long and proven history of life sciences and healthcare investing.
Quintiles Transnational (today IQVIA) is founded to conduct outsourced clinical pharmaceutical trials, growing to become a leading global partner in drug research, development, and data insights
NovaQuest forms as a strategic investment arm within Quintiles Transnational (now IQVIA), laying the foundation for the firm’s product finance and private equity strategies
Investing at Quintiles Transnational
NovaQuest invests over $1 billion across life sciences, pharmaceutical services, and technology
An Independent Firm
NovaQuest Capital becomes an independent firm, spinning out from Quintiles Transnational (IQVIA) to continue its investment strategy
Product Finance Fund III
NovaQuest Capital raises its first institutional fund with approximately $500 million in capital
Product Finance Fund IV
NovaQuest Capital raises approximately $900 million in capital
NovaQuest Capital formalizes separate Private Equity strategy and expands the investment team
NovaQuest Capital continues to invest from its strategic platform
NovaQuest Capital’s expansive network of leading global healthcare partners brings unique operational and strategic advantages to the platform.
Hover on one of our partners to learn more
The world’s largest contract research organization, IQVIA provides biopharmaceutical development and commercial outsourcing services for Phase I-IV clinical trials as well as associated laboratory, analytical, and consulting services.
Mycovia Pharmaceuticals is developing breakthrough therapies in women’s health and dermatology.
Mitsui & Co.
As one of the largest holding companies in the world, Japan-based Mitsui maintains a portfolio of more than 35 healthcare investments across a wide range of healthcare sub-sectors.
Huya Biosciences has aggregated one of the most robust compound portfolios in China covering all major therapeutics areas.
Syneos Health is the only fully integrated biopharmaceutical solutions organization. The company is purpose-built to accelerate customer performance to address modern market realities.
ICON is a Global Contract Research Organisation. They specialise in the strategic development, management and analysis of programs that support Clinical Development; from compound selection to Phase I-IV clinical studies.